284 filings
Page 4 of 15
8-K
CABA
Cabaletta Bio Inc
1 Jun 23
Departure of Directors or Certain Officers
4:05pm
SC 13G
CABA
Cabaletta Bio Inc
26 May 23
Cabaletta Bio / Flynn James E ownership change
3:09pm
8-K
CABA
Cabaletta Bio Inc
22 May 23
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
4:35pm
4
Gwendolyn Binder
19 May 23
Cabaletta Bio / Gwendolyn Binder ownership change
8:10pm
144
Gwendolyn Binder
19 May 23
Notice of proposed sale of securities
4:28pm
8-K
CABA
Cabaletta Bio Inc
18 May 23
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
4:33pm
424B5
CABA
Cabaletta Bio Inc
18 May 23
Prospectus supplement for primary offering
4:29pm
424B5
CABA
Cabaletta Bio Inc
17 May 23
Prospectus supplement for primary offering
9:17pm
8-K
CABA
Cabaletta Bio Inc
16 May 23
Regulation FD Disclosure
4:01pm
8-K
CABA
Cabaletta Bio Inc
16 May 23
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
7:04am
10-Q
2023 Q1
CABA
Cabaletta Bio Inc
Quarterly report
11 May 23
7:38am
8-K
CABA
Cabaletta Bio Inc
11 May 23
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
7:05am
8-K
CABA
Cabaletta Bio Inc
2 May 23
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
4:39pm
8-K
CABA
Cabaletta Bio Inc
1 May 23
Regulation FD Disclosure
7:17am
EFFECT
CABA
Cabaletta Bio Inc
27 Apr 23
Notice of effectiveness
12:15am
CORRESP
CABA
Cabaletta Bio Inc
24 Apr 23
Correspondence with SEC
12:00am
ARS
2022 FY
CABA
Cabaletta Bio Inc
21 Apr 23
Annual report to shareholders
7:04am
DEFA14A
CABA
Cabaletta Bio Inc
21 Apr 23
Additional proxy soliciting materials
7:02am
DEF 14A
CABA
Cabaletta Bio Inc
Definitive proxy
21 Apr 23
7:00am
8-K
CABA
Cabaletta Bio Inc
31 Mar 23
Regulation FD Disclosure
7:14am